Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor-infiltrating lymphocytes (Udai Kammula)
- Development stage
- Unknown
- Lead developer
- Udai Kammula
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational autologous tumor-infiltrating lymphocyte (TIL) therapy is being developed by Dr. Udai Kammula at the UPMC Hillman Cancer Center for the treatment of advanced biliary tract cancers. The therapeutic process involves the surgical extraction of lymphocytes from a patient's tumor, followed by ex vivo expansion and selection for tumor reactivity. These personalized immune cells are then reinfused into the patient following a non-myeloablative lymphodepleting chemotherapy regimen consisting of cyclophosphamide and fludarabine. To enhance the persistence and activity of the infused TILs, patients also receive high-dose aldesleukin (interleukin-2). The therapy is currently being evaluated in a Phase 2 clinical trial (NCT03801083) for patients with locally advanced, recurrent, or metastatic biliary tract cancers, including cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma.
- Other names
- Tumor Infiltrating LymphocytesTILTIL-BTCAdoptive Transfer of Autologous Tumor Infiltrating Lymphocytes
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on autologous tumor-infiltrating lymphocytes (Udai Kammula).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor-infiltrating lymphocytes (Udai Kammula).